Vortioxetine for the treatment of major depressive disorder

Expert Review of Clinical Pharmacology

Volumn 7, Issue 6, 2014, Pages 731-745

  Tritschler, Laurent ^a   Felice, Daniela ^a   Colle, Romain ^b   Guilloux, Jean Philippe ^a   Corruble, Emmanuelle ^b   Gardier, Alain Michel ^a   David, Denis Joseph ^a  

^a University of Paris XI   (France)

^b Universite Paris Sud   (France)

Author keywords

cognition; major depressive disorder; multimodal antidepressant; review; vortioxetine

Indexed keywords

SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN TRANSPORTER; VORTIOXETINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SULFIDE;

ANTIDEPRESSANT ACTIVITY; CLINICAL TRIAL (TOPIC); COGNITION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; MAINTENANCE THERAPY; MAJOR DEPRESSION; NAUSEA; NONHUMAN; REVIEW; RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SLEEP DISORDER; TRANQUILIZING ACTIVITY; VOMITING; ANIMAL; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSIVE DISORDER, MAJOR; HUMANS; PIPERAZINES; SEROTONIN UPTAKE INHIBITORS; SULFIDES;

EID: 84911894667     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.950655     Document Type: Review

References (81)

1. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4- dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011; 54(9):3206-21
2. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113(1):134-53
3. Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997;16(5): 333-8
4. Greenshaw AJ. Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential. Trends Pharmacol Sci 1993;14(7):265-70
5. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J Psychopharm 2010;24(4):455-69
6. Abbas AI, Hedlund PB, Huang XP, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009;205(1): 119-28
7. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG. 5-HT7 receptor inhibition and inactivation induce antidepressant-like behavior and sleep pattern. Biol Psychiatry 2005;58(10):831-7
8. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E. Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 2006;51(3):578-86
9. Harsing LG Jr, Prauda I, Barkoczy J, et al. A 5-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction. Neurochem Res 2004;29(8):1487-97
10. Mørk A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav 2013;105:41-50
11. Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wojcik E. Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Behav Pharmacol 2004;15(8):523-34
12. Chenu F, David DJ, Leroux-Nicollet I, et al. Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system. J Psychiatry Neurosci 2008;33(6): 541-50
13. O'Neill MF, Conway MW. Role of 5-HT (1A) and 5-HT(1B) receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 2001;24(4):391-8
14. de Groote L, Klompmakers AA, Olivier B, Westenberg HG. Role of extracellular serotonin levels in the effect of 5-HT1B receptor blockade. Psychopharmacology (Berl) 2003;167(2):153-8
15. Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012;340(3):666-75
16. Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters - a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2013; 23(2):133-45
17. Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010;65(1):7-19
18. Blier P, de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15(7):220-6
19. Betry C, Pehrson AL, Etievant A, et al. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Int J Neuropsychopharmacol 2013;16(5):1115-27
20. Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road to remission? Science 2012;338(6103):72-5
21. Mendez-David I, Hen R, Gardier AM, David DJ. Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann Pharm Fr 2013;71(3):143-9
22. Guilloux JP, Mendez-David I, Pehrson A, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 2013;73:147-59
23. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014; 19(2):121-33
24. Anisman H, Hayley S, Kelly O, et al. Psychogenic, neurogenic, and systemic stressor effects on plasma corticosterone and behavior: mouse strain-dependent outcomes. Behav Neurosci 2001;115(2):443-54
25. Kim S, Lee S, Ryu S, et al. Comparative analysis of the anxiety-related behaviors in four inbred mice. Behav Processes 2002; 60(2):181-90
26. Neumann ID, Wegener G, Homberg JR, et al. Animal models of depression and anxiety: what do they tell us about human condition? Prog Neuropsychopharmacol Biol Psychiatry 2011;35(6):1357-75
27. Overstreet DH, Wegener G. The flinders sensitive line rat model of depression - 25 years and still producing. Pharmacol Rev 2013;65(1):143-55
28. Li Y, Raaby KF, Sanchez C, Gulinello M. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res 2013;256:520-8
29. Jensen JB, du Jardin KG, Song D, et al. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur Neuropsychopharmacol 2014;24(1):148-59
30. du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 2014;24(1):160-71
31. Wallace A, Pehrson AL, Sanchez C, Morilak DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014;1-12
32. Leiser SC, Pehrson AL, Robichaud PJ, Sanchez C. The multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine - a quantitative electroencephalographic study in the rat. Br J Pharmacol 2014;In press
33. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52(2):90-110
34. Venzala E, Garcia-Garcia AL, Elizalde N, et al. Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors. Psychopharmacology (Berl) 2012;224(2): 313-25
35. David DJ, Samuels BA, Rainer Q, et al. Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 2009;62(4): 479-93
36. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007;32(2):86-102
37. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study. Am J Psychiatry 2004;161(5):826-35
38. Areberg J, Luntang-Jensen M, Sogaard B, Nilausen DO. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol 2012;110(4):401-4
39. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int Clin Psychopharmacol 2012;15(5):589-600
40. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012; 22(7):482-91
41. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73(7):953-9
42. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27(4):215-23
43. Chen G, Lee R, Hojer AM, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013; 33(10):727-36
44. Areberg J, Petersen KB, Chen G, Naik H. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol 2014;In press
45. Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012;40(7): 1357-65
46. Wang Y, Wojtkowski T, Devoti A, et al. Effect of Lu AA21004 on the pharmacokinetics and pharmacodynamics of ethinyl estradiol (30 lg) and levonorgestrel (150 lg) in healthy adult women. J Clin Pharmacol 2009;49:1114
47. Wang Y, Zhang W, Agyeman A, et al. Lack of effect of multiple doses of Lu AA21004 on the pharmacodynamics and pharmacokinetics of aspirin. J Clin Pharmacol 2010;50:1082
48. Efficacy and safety study of vortioxetine (Lu AA21004) for treatment of major depressive disorder. Available from: http://clinicaltrials. gov/show/NCT01255787
49. Khin NA, Chen YF, Yang Y, et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 2011;72(4):464-72
50. Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol 2012; 22(12):847-57
51. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012;26(11):1408-16
52. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int Clin Psychopharmacol 2013;16(2):313-21
53. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013;29(3):217-26
54. ClinicalTrials.gov. Available from: www. ClinicalTrials.gov database
55. Safety and efficacy study of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials. gov/show/NCT01179516
56. Efficacy and safety study of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials. gov/show/NCT01163266
57. Safety and efficacy of vortioxetine (Lu AA21004) in adults with major depressive disorder. Available from: http://clinicaltrials. gov/show/NCT01153009
58. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29(3):138-49
59. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int Clin Psychopharmacol 2014;1-11
60. Marazziti D, Consoli G, Picchetti M, et al. Cognitive impairment in major depression. Eur J Pharmacol 2010;626(1):83-6
61. Trivedi MH, Greer TL. Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord 2014;152-154:19-27
62. Cowen P, Sherwood AC. The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J Psychopharmacol 2013;27(7):575-83
63. Theunissen EL, Street D, Hojer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013;93(6):493-501
64. Cassano GB, Puca F, Scapicchio PL, Trabucchi M. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002;63(5):396-402
65. Gallassi R, Di Sarro R, Morreale A, Amore M. Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J Affect Disord 2006;91(2-3):243-50
66. Levkovitz Y, Caftori R, Avital A, Richter-Levin G. The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res Bull 2002;58(4): 345-50
67. Richardson JS, Keegan DL, Bowen RC, et al. Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. Int Clin Psychopharmacol 1994;9(1):35-40
68. Mahableshwarkar AR, Zajecka J, Jacobson W, et al. Efficacy of vortioxetine on cognitive function in adult patients with major depressive disorder: results of a randomized, double blind, active referenced, placebo-controlled trial. Presented at the 29th World Congress of the International College of Neuropsychopharmacology; Vaccouver, Canada; 2014; Poster LP-02
69. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014;29(1):36-44
70. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012;28(10):1717-24
71. Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol 2014;29(1):64-72
72. Baldwin DS, Serenko M, Palo W, et al. The safety and tolerability of vortioxetine (LuAA21004) in the treatment of adults with major depressive disorder (MDD): pooled analysis. Int J Psychiatry 2013;17: 16-17
73. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009;29(2):157-64
74. Jacobsen PL, Mahableswarkar AR, Chen Y, et al. A head to head, randomized, comparison study of vortioxetine vs. escitalopram in patients well treated for MDD and experiencing treatment-emergent sexual dysfunction. Presented at the Annual Meeting Of The American Society of Clinical Psychopharmacology; 16 - 19 June 2014; Hollywood, FL, USA; Poster 41
75. Luca A, Luca M, Calandra C. Sleep disorders and depression: brief review of the literature, case report, and nonpharmacologic interventions for depression. Clin Interv Aging 2013;8: 1033-9
76. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005;20(8):533-59
77. Jacobsen PL, Mahableswarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adult with major depressive disorder. Presented at the American Psychiatric Association 166th Annual Meeting; 18 - 22 May 2013; San Francisco, CA, USA Poster NR9-06
78. Mahableshwarkar AR, Chen MY, Trivedi MH. A duloxetine-referenced, fixed-dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult MDD patients. Presented at the American Psychiatric Association 166th Annual Meeting; 18 - 22 May 2013; San Francisco, CA, USA; Poster NR9-01
79. Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014;68(1):60-82
80. Takeda Pharmaceutical America I. BRINTELLIX (vortioxetine) tablets, for oral use. Prescribing information. Revised September 2013 Available from: http:// general.takedapharm.com/content/file/pi.pdf? applicationcode=396066C6-E50F-4113- ABAD-54FE9525BF7E&filetypecode= BRINTELLIXPI 2013
81. Fu J, Chen Y. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis. Psychopharmacology (Berl) 2014. In press